Anavex received FDA clearance for its IND application evaluating blarcamesine for Fragile X syndrome, marking progress toward clinical trials for the condition with no approved treatments. This opens INDs for the drug in all three core indications.
Anavex received FDA clearance for its IND application evaluating blarcamesine for Fragile X syndrome, marking progress toward clinical trials for the condition with no approved treatments. This opens INDs for the drug in all three core indications.